EBV-based gene therapy (Amgen)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug NameEBV-based gene therapy (Amgen)
Drug Alias NameEBV-gene therapy (Immunex)oncolytic EBV therapy (Amgen)EBNA-1 gene therapy (Immunex)adv.oriP.E1A. (Immunex)
ClassificationBiologics > Oncolytic virusCell and gene therapy > Gene therapy > Viral vector-based gene therapy
Mechanisms of ActionImmunostimulants
TargetsUpdating
Therapy Area/IndicationsNasopharyngeal CarcinomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesImmunex Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmgen IncImmunex Corp
Active IndicationsN/A
Inactive IndicationsNasopharyngeal CarcinomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A